IMTX / Down -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)

Immatics (IMTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong more_horizontal

Immatics showcases a robust financial position and promising IMA203 TCR-T cell therapy for oncology with impressive safety and efficacy data. Risks in more_horizontal

Immatics NV's shares rose Monday after it announced a collaboration with Moderna Therapeutics Inc (NASDAQ:MRNA) to pioneer novel and transformative t more_horizontal

Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer more_horizontal

Immatics (IMTX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0. more_horizontal

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revision more_horizontal

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revision more_horizontal

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the more_horizontal